Abstract
Based on reinforced urn process introduced by Muliere et al. [2000. Urn schemes and reinforced random walks. Stochastic Process. Appl. 88(1), 59–78] we propose a Bayesian nonparametric approach to analyse a design determining the maximum tolerated dose (MTD) in Phase I clinical trials for new drug development when intrapatient dose escalation is allowed. A predictive distribution of MTD is obtained and its point estimation may consist in the corresponding expected value.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
